Who makes NEMO-103 Injection?

NEMO-103 Injection is developed by Inventera Inc..

What development phase is NEMO-103 Injection in?

NEMO-103 Injection is in Phase 3.

Last reviewed 2026-04-23 · How we verify

NEMO-103 Injection

Inventera Inc. · Phase 3 active Small molecule

NEMO-103 Injection's mechanism is not publicly available.

At a glance

Generic name	NEMO-103 Injection
Sponsor	Inventera Inc.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Unfortunately, there is limited information available on the exact mechanism of action of NEMO-103 Injection.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 3 Study of the Efficacy and Safety of MR Arthrography Using the NEMO-103 Injection in Patients With Known or Suspected Shoulder Joint Diseases (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NEMO-103 Injection CI brief — competitive landscape report
NEMO-103 Injection updates RSS · CI watch RSS
Inventera Inc. portfolio CI